AI assistant
Oncopeptides — Director's Dealing 2017
Feb 24, 2017
3091_iss_2017-02-24_3a3563c1-185d-4219-97c6-ed8fa87c0441.pdf
Director's Dealing
Open in viewerOpens in your device viewer
Stockholm, Sweden February 24, 2017
Company's CEO Acquires Shares in Oncopeptides
Stockholm, Sweden - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the company's CEO, Jakob Lindberg acquired 45,000 shares in Oncopeptides for a value of SEK 1.9M in addition to the shares that he subscribed for in the recent share issue in connection with the IPO.
For further information, please contact: Jakob Lindberg, CEO at Oncopeptides E-mail: [email protected]
Rein Piir, Head of Investor Relations at Oncopeptides E-mail: [email protected] Mobil: +46 708537292
This information is information that Oncopeptides is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on February 24, 2017 at 14.00 a.m. (CET).
About Oncopeptides
Oncopeptides is a research and development stage pharmaceutical company developing drugs for treatment of cancer. Since the founding of the Company in 2000, the Company has focused primarily on the development of the product candidate Ygalo, an innovative peptidase-potentiated alkylator intended for effective and focused treatment of blood-based cancer diseases, and in particular multiple myeloma. Ygalo is intended to demonstrate better results from treatment compared to established alternative drugs in the treatment of patients with multiple myeloma. Ygalo could potentially provide treating physicians with a new treatment option for patients suffering from this severe cancer disease.